secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0001787400-26-000005
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta reports FY2025 net loss of $104.1M; cash runway into 2029
----------------------------------------------------------------

- Cash, equivalents and investments $295.1M at Dec 31, 2025; expected to fund operations into 2029.
- Full-year net loss $104.1M ($1.41 per share); Q4 net loss $27.4M ($0.37 per share).
- NKX019 dose escalation advanced to 4 billion cells per dose in Ntrust-1 and Ntrust-2 trials.
- Initial clinical data from Ntrust-1 and Ntrust-2 planned for presentation at a medical conference in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000178740026000005/0001787400-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000178740026000005/nktx-20260325.htm
  HTML page:      https://secwatch.observer/filing/0001787400-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer